Litcius/Paper detail

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

Nathalie Baize, I. Monnet, Laurent Greillier, Margaux Geier, H. Léna, Henri Janicot, A. Vergnenègre, Jacky Créquit, R. Lamy, J.B. Auliac, J. Letreut, H. Le Caer, Radj Gervais, Éric Dansin, Anne Madroszyk, P Renault, G. Le Garff, L. Falchero, H. Bérard, Roland Schött, Patrick Saulnier, C. Chouaïd

2020The Lancet Oncology153 citationsDOI

Topics & Concepts

TopotecanCarboplatinMedicineEtoposideOpen labelOncologyLung cancerSecond line treatmentInternal medicineClinical trialSurgeryChemotherapyCisplatinLung Cancer Research StudiesLung Cancer Treatments and MutationsNeuroendocrine Tumor Research Advances
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial | Litcius